Pharma Roundup: Glaxo Reorganizing in U.S., Pfizer Urged to Keep Jobs in Connecticut, and More

Recommended Sources

About Pharma Industry

BNET Pharma provides daily industry trends and news coverage with insights for managers and executives about major manufacturers of pharmaceuticals and medicine. In addition to detailed drug company profiles, we bring you industry analysis on new partnerships, drug patents and products, cost management, investments, pharmaceutical related lawsuits, and a host of other important business issues.

Glaxo reorganizes U.S. operations — Final details of the changes are planned for release on Wednesday, November 5. Cuts to sales rep teams are expected; a new head of Glaxo North America (the current head, Chris Viehbacher, is leaving to lead Sanofi), however, will not yet be named. [Source: Pharmalot]

Connecticut congressmen ask Pfizer to keep U.S. jobs — Pfizer has significant operations in the state, and fears have grown that the company is grooming foreign workers to take over the IT work Connecticut contractors currently perform. Senator Chris Dodd and Representative Joe Courtney voiced their concerns in an open letter. [Source: WSJ Health Blog]

AstraZeneca executive Patterson to retire — In March, John Patterson will leave his post leading the company’s development organization. [Source: PharmaGossip]

DTC advertising not earning its keep — … or so says John Mack, at the Pharma Marketing Blog. Mack crunched some numbers and determined that, contrary to conventional wisdom, pharma would profit from the elimination of direct-to-consumer TV ads (i.e., sales generated by DTC ads don’t cover their cost). Agree or disagree with his math, it’s a provocative point. [Source: Pharma Marketing Blog]

Tags: U.S., Job, Pfizer Inc., Connecticut, Glaxo, Recruitment & Selection, Human Resources, Workforce Management, John Maas, Advertisement, Pharmaceutical Company, Sales Strategy, Sales

BNET User Analysis

Voice your 2cents

BNET TalkbackShare your ideas and expertise on this topic

Subscribe to this discussion via Email or RSS

1

eboneian

11/05/08 | Report as spam

RE: Pharma Roundup: Glaxo Reorganizing in U.S., Pfizer Urged to Keep Jobs in Connecticut, and More

I feel that cutting back on ads and CEO and other executive bonuses and perks to keep vested employees employed would build morale heighten productivity and possibly innovation and creativity.

Bring the jobs back to the USA!
2

Not Assimilated

11/05/08 | Report as spam

RE: Pharma Roundup: Glaxo Reorganizing in U.S., Pfizer Urged to Keep Jobs in Connecticut, and More

Pfizer is the Borg of big pharma. The Borg doesn???t invent???it only takes over what belongs to others with the warning ???Assimilate or die.??? Pfizer buys other companies, lays off all the workers of the ???assimilated??? company, and sells all the assets except, of course, the drug patents.

Because Pfizer laid off the majority of its brain trust, it is left with a dwindling pipleline but a heap of cash. Pfizer hasn???t come up with a novel drug on its own in a very long time. The big-name drugs it owns came from those ???assimilations??? (Lipitor, Gabapentin, Viagra, Rogaine, and many others).

The Borg strategy is not working. Pfizer stock is 1/2 its 2000 value. Sure, it???s sitting on $40B cash???that???s a lot of dividends to spread around. But don???t mistake that for actual growth.